Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study

Advances in Therapy ◽

10.1007/s12325-021-01899-0 ◽

2021 ◽

Author(s):

Lin Cai ◽

Linfeng Li ◽

Hao Cheng ◽

Yangfeng Ding ◽

Zhenshu Biao ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Severe Plaque Psoriasis ◽

Phase Iii Study

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718340215.793493941 ◽

2014 ◽

Author(s):

Kamran Ghoreschi ◽

Sebastian Volc

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Chronic Plaque Psoriasis ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2014.01.897 ◽

2014 ◽

Vol 71 (3) ◽

pp. 484-492 ◽

Cited By ~ 49

Author(s):

D.S. Krupashankar ◽

Sunil Dogra ◽

Mahendra Kura ◽

Abir Saraswat ◽

Leelavathy Budamakuntla ◽

...

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Chronic Plaque Psoriasis ◽

Double Blind ◽

Phase Iii Study

Download Full-text

Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2016.12.014 ◽

2017 ◽

Vol 76 (6) ◽

pp. 1093-1102 ◽

Cited By ~ 51

Author(s):

Kim Papp ◽

Herve Bachelez ◽

Antonio Costanzo ◽

Peter Foley ◽

Melinda Gooderham ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Double Blind ◽

Severe Plaque Psoriasis ◽

Multicenter Phase ◽

Phase Iii Study ◽

Abp 501

Download Full-text

Efficacy and safety of brodalumab in the Korean population for the treatment of moderate to severe plaque psoriasis: A randomized, phase III, double‐blind, placebo‐controlled study

The Journal of Dermatology ◽

10.1111/1346-8138.15733 ◽

2020 ◽

Author(s):

Seong Jun Seo ◽

Bong Seok Shin ◽

Joo‐Heung Lee ◽

Haeyoun Jeong

Keyword(s):

Plaque Psoriasis ◽

Korean Population ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis

Download Full-text

Efficacy and safety of ixekizumab in a phase III , randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis ( IXORA ‐ PEDS )

British Journal of Dermatology ◽

10.1111/bjd.19147 ◽

2020 ◽

Vol 183 (2) ◽

pp. 231-241 ◽

Cited By ~ 8

Author(s):

A.S. Paller ◽

M.M.B. Seyger ◽

G. Alejandro Magariños ◽

J. Bagel ◽

A. Pinter ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Severe Plaque Psoriasis ◽

Paediatric Patients

Download Full-text

Sustained long‐term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double‐blind, phase III study

British Journal of Dermatology ◽

10.1111/bjd.18029 ◽

2019 ◽

Vol 181 (6) ◽

pp. 1177-1189 ◽

Cited By ~ 5

Author(s):

D. Thaçi ◽

K. Papp ◽

D. Marcoux ◽

L. Weibel ◽

A. Pinter ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Chronic Plaque Psoriasis ◽

Double Blind ◽

Term Efficacy ◽

Paediatric Patients ◽

Phase Iii Study

Download Full-text

Efficacy and safety of a novel formulation of an oral fumarate, BG-12, in patients with moderate to severe plaque psoriasis: Results of a phase III study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2004.10.740 ◽

2005 ◽

Vol 52 (3) ◽

pp. P182

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phase Iii Study

Download Full-text

Efficacy and safety of secukinumab in Taiwanese patients with moderate to severe plaque psoriasis: Subanalysis from ERASURE phase III study

The Journal of Dermatology ◽

10.1111/1346-8138.13900 ◽

2017 ◽

Vol 44 (10) ◽

pp. 1129-1137 ◽

Cited By ~ 14

Author(s):

Nan-Lin Wu ◽

Chih-Jung Hsu ◽

Fang-Ju Sun ◽

Tsen-Fang Tsai

Keyword(s):

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phase Iii Study

Download Full-text

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Case Medical Research ◽

10.31525/ct1-nct04033354 ◽

2019 ◽

Author(s):

Keyword(s):

Stage Iiib ◽

Phase Iii ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

A Randomized, Double-blind, Placebo‑Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Case Medical Research ◽

10.31525/ct1-nct04063163 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

Extensive Stage

Download Full-text